While B-ALL is the most common childhood cancer and one of the most treatable, some patients face grim outcomes after they ...

Researchers identified a six-gene pattern predicting venetoclax response in multiple myeloma. This genetic insight allows for ...

The single-center report showed the therapy had a favorable safety profile and manageable side effects in children with ...

Researchers found no significant differences in the risk of overall adverse events (AEs), but there were significant differences in grade 3 or higher AEs, serious AEs, treatment discontinuations due ...

ImCheck to Present Encouraging Interim Results in AML Patients from the EVICTION Trial at the 66th American Society of Hematology Annual ...

The new report is an attempt to provide comprehensive safety data on the rapidly changing treatment landscape for relapsed or ...

Colorado, USA-based OncoVerity announced the closing of a series A extension led by existing investors, argenX and ...

The firm will track the activity of the triplet broadly in AML patients, including in those with FLT3, NRAS, and TP53 mutations.

The proceeds from the Series A extension will fund the Phase 2 OV-AML-1231 trial of cusatuzumab, a novel, first-in-class high ...

Aptose Biosciences (APTO) announced initiation of the TUSCANY study, tuspetinib, TUS, in combination therapy with azacitidine, AZA, and ...

TUSCANY study is open to enroll patients to receive TUS+VEN+AZA triplet at select US sites Favorable safety and broad clinical activity make tuspetinib an ideal agent to combine with venetoclax and ...